| ²é¿´: 682 | »Ø¸´: 2 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
sunxing1234гæ (³õÈëÎÄ̳)
|
[ÇóÖú]
Õæ³ÏÇóÖú¹ØÓÚBPÒ©µä¸½¼þµÄÎÊÌ⣡£¡£¡--ÔÚÏßµÈ ÒÑÓÐ1È˲ÎÓë
|
||
|
BPÖо³£»áÓÐÕâÑùÒ»¶Î»°£ºOther detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use): K. ÎÊÌâÊÇ¡°See also 5.10¡±ÊǵÄʲôÄÚÈÝ£¿ ¹òлÐֵܽãÃã¡£¡ |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸211£¬0703»¯Ñ§305·ÖÇóµ÷¼Á
ÒѾÓÐ9È˻ظ´
22408 µ÷¼Á²ÄÁÏ
ÒѾÓÐ5È˻ظ´
273Çóµ÷¼Á
ÒѾÓÐ23È˻ظ´
Ò»Ö¾Ô¸»ª¶«Àí¹¤085601²ÄÁϹ¤³Ì303·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
0703»¯Ñ§
ÒѾÓÐ22È˻ظ´
»ªÄÏÀí¹¤0703»¯Ñ§£¬×Ü·Ö336Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
³õÊÔ301£¬´úÂë085701»·¾³¹¤³Ì£¬±¾Ë¶Ò»Ö£¬ËÄÁù¼¶Òѹý£¬ÓжþÇøÒ»×÷£¬¹²·¢±í5ƪÂÛÎÄ
ÒѾÓÐ10È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
Ò»Ö¾Ô¸ÉϺ£º£Ñó´óѧ083200ʳƷѧ˶£¬Çóµ÷¼Á£¬½ÓÊÜÆäËûרҵ
ÒѾÓÐ10È˻ظ´
µ÷¼Á
ÒѾÓÐ11È˻ظ´
sunxing1234
гæ (³õÈëÎÄ̳)
![]() |
3Â¥2015-11-07 10:12:39
klicking
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- ACI: 9
- Ó¦Öú: 923 (²©ºó)
- ¹ó±ö: 0.652
- ½ð±Ò: 19319.5
- É¢½ð: 30
- ºì»¨: 149
- ɳ·¢: 1
- Ìû×Ó: 2337
- ÔÚÏß: 513.3Сʱ
- ³æºÅ: 1426293
- ×¢²á: 2011-10-03
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
xl_pro: ½ð±Ò+2, ¸ÐлÄãµÄÓ¦Öú£¬ÐÁ¿àÁË£¡ 2015-11-08 11:08:23
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
xl_pro: ½ð±Ò+2, ¸ÐлÄãµÄÓ¦Öú£¬ÐÁ¿àÁË£¡ 2015-11-08 11:08:23
| ÕâÓ¦¸ÃÊÇָŷÖÞÒ©µäͨÔò5.10 Control of impurities in substances for pharmaceutical use |
» ±¾Ìû¸½¼þ×ÊÔ´Áбí
-
»¶Ó¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com - ¸½¼þ 1 : 5.10.pdf
2015-11-07 07:47:30, 252.35 K

2Â¥2015-11-07 07:47:34














»Ø¸´´ËÂ¥